This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Small, E. J. Articles by Reese, D. M. Search for Related Content PubMed PubMed Citation Articles by Small, E. J. Articles by Reese, D. M.

Prospective Trial of the Herbal Supplement PC-SPES in Patients With Progressive Prostate Cancer

From the University of California at San Francisco, San Francisco, CA; and Memorial Sloan-Kettering Cancer Center, New York, NY.

Address reprint requests to Eric J. Small, MD, University of California at San Francisco, UCSF Comprehensive Cancer Center, 1600 Divisadero, 3rd Floor, San Francisco, CA 94115; email smalle{at}medicine.ucsf.edu

ABSTRACT

PURPOSE: PC-SPES is an herbal supplement for which there are anecdotal reports of anti–prostate cancer activity. This phase II study was undertaken to assess the efficacy and toxicity of PC-SPES in prostate cancer patients.

PATIENTS AND METHODS: Thirty-three patients with androgen-dependent prostate cancer (ADPCa) and 37 patients with androgen-independent prostate cancer (AIPCa) were treated with PC-SPES at a dose of nine capsules daily. Clinical outcome was assessed with serial serum prostate-specific androgen (PSA) level measurement and imaging studies.

RESULTS: One hundred percent of ADPCa patients experienced a PSA decline of 80%, with a median duration of 57+ weeks. No patient has developed PSA progression. Thirty-one patients (97%) had declines of testosterone to the anorchid range. Two ADPCa patients had positive bone scans; both improved. One patient with a bladder mass measurable on computed tomography scan experienced disappearance of this mass. Nineteen (54%) of 35 AIPCa patients had a PSA decline of 50%, including eight (50%) of 16 patients who had received prior ketoconazole therapy. Median time to PSA progression was 16 weeks (range, 2 to 69+ weeks). Of 25 patients with positive bone scans, two had improvement, seven had stable disease, 11 had progressive disease, and five did not have a repeat bone scan because of PSA progression. Severe toxicities included thromboembolic events (n = 3) and allergic reactions (n = 3). Other frequent toxicities included gynecomastia/gynecodynia, leg cramps, and grade 1 or 2 diarrhea.

CONCLUSION: PC-SPES seems to have activity in the treatment of both ADPCa and AIPCa and has acceptable toxicity. Further study is required to determine whether its effects exceed those expected with estrogen therapy.

NOTES

Presented in part at the Thirty-Fifth Annual Meeting of the American Society for Clinical Oncology, Atlanta, GA, May 15-18, 1999.

This article has been cited by other articles:

				A. Munshi, L. H. Ni, and M. S. Tiwana Complementary and Alternative Medicine in Present Day Oncology Care: Promises and Pitfalls Jpn. J. Clin. Oncol., August 5, 2008; (2008) hyn066v1. [Abstract] [Full Text] [PDF]

				D. R. Yance Jr and S. M. Sagar Targeting angiogenesis with integrative cancer therapies. Integr Cancer Ther, March 1, 2006; 5(1): 9 - 29. [Abstract] [PDF]

				A. J. Vickers, J. Kuo, and B. R. Cassileth Unconventional Anticancer Agents: A Systematic Review of Clinical Trials J. Clin. Oncol., January 1, 2006; 24(1): 136 - 140. [Abstract] [Full Text] [PDF]

				D. R. Berthold, C. N. Sternberg, and I. F. Tannock Management of Advanced Prostate Cancer After First-Line Chemotherapy J. Clin. Oncol., November 10, 2005; 23(32): 8247 - 8252. [Abstract] [Full Text] [PDF]

				G. K. Dy, L. Bekele, L. J. Hanson, A. Furth, S. Mandrekar, J. A. Sloan, and A. A. Adjei Complementary and Alternative Medicine Use by Patients Enrolled Onto Phase I Clinical Trials J. Clin. Oncol., December 1, 2004; 22(23): 4810 - 4815. [Abstract] [Full Text] [PDF]

				M. P. Kosty PC-SPES: Hope or Hype? J. Clin. Oncol., September 15, 2004; 22(18): 3657 - 3659. [Full Text] [PDF]

				W. K. Oh, P. W. Kantoff, V. Weinberg, G. Jones, B. I. Rini, M. K. Derynck, R. Bok, M. R. Smith, G. J. Bubley, R. T. Rosen, et al. Prospective, Multicenter, Randomized Phase II Trial of the Herbal Supplement, PC-SPES, and Diethylstilbestrol in Patients With Androgen-Independent Prostate Cancer J. Clin. Oncol., September 15, 2004; 22(18): 3705 - 3712. [Abstract] [Full Text] [PDF]

				B. R. Cassileth and G. Deng Complementary and Alternative Therapies for Cancer Oncologist, February 1, 2004; 9(1): 80 - 89. [Abstract] [Full Text] [PDF]

				T. Ikezoe, Y. Yang, D. Heber, H. Taguchi, and H. P. Koeffler PC-SPES: A Potent Inhibitor of Nuclear Factor-{kappa}B Rescues Mice from Lipopolysaccharide-Induced Septic Shock Mol. Pharmacol., December 1, 2003; 64(6): 1521 - 1529. [Abstract] [Full Text] [PDF]

				D. Spentzos, C. Mantzoros, M. M. Regan, M. E. Morrissey, S. Duggan, S. Flickner-Garvey, H. McCormick, W. DeWolf, S. Balk, and G. J. Bubley Minimal Effect of a Low-Fat/High Soy Diet for Asymptomatic, Hormonally Naive Prostate Cancer Patients Clin. Cancer Res., August 1, 2003; 9(9): 3282 - 3287. [Abstract] [Full Text] [PDF]

				T. Wadsworth, H. Poonyagariyagorn, E. Sullivan, D. Koop, and C. E. Roselli In Vivo Effect of PC-SPES on Prostate Growth and Hepatic CYP3A Expression in Rats J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 187 - 194. [Abstract] [Full Text] [PDF]

				S. Wilkinson and G. W. Chodak Critical Review of Complementary Therapies for Prostate Cancer J. Clin. Oncol., June 1, 2003; 21(11): 2199 - 2210. [Abstract] [Full Text] [PDF]

				W. A. Weiger, M. Smith, H. Boon, M. A. Richardson, T. J. Kaptchuk, and D. M. Eisenberg Advising Patients Who Seek Complementary and Alternative Medical Therapies for Cancer Ann Intern Med, December 3, 2002; 137(11): 889 - 903. [Abstract] [Full Text] [PDF]

				M. J. Bonham, A. Galkin, B. Montgomery, W. L. Stahl, D. Agus, and P. S. Nelson Effects of the Herbal Extract PC-SPES on Microtubule Dynamics and Paclitaxel-Mediated Prostate Tumor Growth Inhibition J Natl Cancer Inst, November 6, 2002; 94(21): 1641 - 1647. [Abstract] [Full Text] [PDF]

				T.-c. Hsieh, X. Lu, J. Chea, and J. M. Wu Prevention and Management of Prostate Cancer Using PC-SPES: A Scientific Perspective J. Nutr., November 1, 2002; 132(11): 3513S - 3517. [Abstract] [Full Text] [PDF]

				S. Huerta, J. R. Arteaga, R. W. Irwin, T. Ikezoe, D. Heber, and H. P. Koeffler PC-SPES Inhibits Colon Cancer Growth in Vitro and in Vivo Cancer Res., September 15, 2002; 62(18): 5204 - 5209. [Abstract] [Full Text] [PDF]

				J. White PC-SPES-A Lesson for Future Dietary Supplement Research J Natl Cancer Inst, September 4, 2002; 94(17): 1261 - 1262. [Full Text] [PDF]

				M. Sovak, A. L. Seligson, M. Konas, M. Hajduch, M. Dolezal, M. Machala, and R. Nagourney Herbal Composition PC-SPES for Management of Prostate Cancer: Identification of Active Principles J Natl Cancer Inst, September 4, 2002; 94(17): 1275 - 1280. [Abstract] [Full Text] [PDF]

				M. Bonham, H. Arnold, B. Montgomery, and P. S. Nelson Molecular Effects of the Herbal Compound PC-SPES: Identification of Activity Pathways in Prostate Carcinoma Cancer Res., July 15, 2002; 62(14): 3920 - 3924. [Abstract] [Full Text] [PDF]

				B. A. Hellerstedt and K. J. Pienta The Current State of Hormonal Therapy for Prostate Cancer CA Cancer J Clin, May 1, 2002; 52(3): 154 - 179. [Abstract] [Full Text] [PDF]

				J. S. Jacobson, A. B. Troxel, J. Evans, L. Klaus, L. Vahdat, D. Kinne, K. M. S. Lo, A. Moore, P. J. Rosenman, E. L. Kaufman, et al. Randomized Trial of Black Cohosh for the Treatment of Hot Flashes Among Women With a History of Breast Cancer J. Clin. Oncol., May 15, 2001; 19(10): 2739 - 2745. [Abstract] [Full Text] [PDF]

				T. Ades, T. Gansler, M. Miller, and D. S. Rosenthal PC-SPES: Current Evidence and Remaining Questions CA Cancer J Clin, May 1, 2001; 51(3): 199 - 204. [Full Text] [PDF]